Literature DB >> 3814466

Estimating the clearance of amylobarbitone from a single plasma measurement.

K Bachmann.   

Abstract

Amylobarbitone sodium (200 mg) was given by intravenous injection to nine healthy, young adults (four males). Subjects were drug-free and nonsmokers. Serial blood samples were drawn for 48 h following the infusion, and multiple sample and single sample estimates of clearance were calculated. The mean (+/- s.d.) values for clearance (CL) and apparent volume of distribution (V) were 0.032 (+/- 0.007) 1 h-1 kg-1 and 1.08 (+/- 0.16) 1 kg-1, respectively. The mean (+/- s.d.) single sample estimate of clearance, CL, based on just the 48 h plasma concentrations of amylobarbitone was 0.033 (+/- 0.006) 1 h-1 kg-1. The 48 h single sample CL value was shown to reliably reflect the value of CL with little bias and good precision. Values of the 48 h CL when compared to CL exhibited a mean prediction error (mpe) of 1.2% with 95% confidence limits of -6.3% to 9.4%, and a root mean squared error (rmse) of 9.4%. It is concluded that amylobarbitone's clearance can be estimated in a single dose, single sample protocol permitting its use as a single dose, single sample probe for studying host factor influences on drug metabolism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3814466      PMCID: PMC1386147          DOI: 10.1111/j.1365-2125.1987.tb03016.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.

Authors:  G W Hepner; E S Vesell; A Lipton; H A Harvey; G R Wilkinson; S Schenker
Journal:  J Lab Clin Med       Date:  1977-09

2.  Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs.

Authors:  B H Dvorchik; E S Vessell
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

3.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

4.  ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates.

Authors:  R D Brown; J E Manno
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

5.  Prediction of maintenance dose required to attain a desired drug concentration at steady-state from a single determination of concentration after an initial dose.

Authors:  J T Slattery; M Gibaldi; J R Koup
Journal:  Clin Pharmacokinet       Date:  1980 Jul-Aug       Impact factor: 6.447

6.  Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

Authors:  L G Sultatos; B H Dvorchik; E S Vesell; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

7.  Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine.

Authors:  G W Hepner; E S Vesell
Journal:  Ann Intern Med       Date:  1975-11       Impact factor: 25.391

8.  Amobarbital--a probe of hepatic drug oxidation in man.

Authors:  T Inaba; B K Tang; L Endrenyi; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

9.  The kinetics of amylobarbitone metabolism in healthy men and women.

Authors:  K Balasubramaniam; S B Lucas; G E Mawer; P J Simons
Journal:  Br J Pharmacol       Date:  1970-07       Impact factor: 8.739

10.  Screening for the influence of host factors on warfarin clearance using a single dose single sample procedure.

Authors:  K Bachmann
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1986-04
View more
  1 in total

1.  Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements.

Authors:  K A Bachmann; J I Schwartz; L Jauregui
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.